Y's Therapeutics Co., Ltd. Initiates Phase II Clinical Program To Evaluate YSPSL In Prevention Of Delayed Graft Function
11/29/2005 10:41:46 AM
More...
|
Y's Therapeutics Co., Ltd. Appoints John Wulf As Head Of U.S. Operations And Global Chief Business Officer
10/19/2005 5:11:45 PM
More...
|
Y's Therapeutics Co., Ltd. Files To Begin Two Phase II Clinical Trials In Europe For Rheumatoid Arthritis And Asthma
10/19/2005 5:11:35 PM
More...
|
Y's Therapeutics Co., Ltd. And Lonza Group Announce Development/Manufacturing Agreement
10/19/2005 5:10:43 PM
More...
|
Y's Therapeutics Co., Ltd. And Abmaxis, Inc. Announce Antibody Collaboration
10/19/2005 5:10:13 PM
More...
|
Y's Therapeutics Co., Ltd. Raises 2.4 Billion Yen (US $22 Million) In Series B Financing
10/19/2005 5:10:05 PM
More...
|